Recent Price Movement and Market Context
On 6 Feb 2026, TTK Healthcare’s share price declined by 0.68% during the trading session, closing at the fresh 52-week low of Rs.947.65. This follows a consecutive two-day fall, with the stock losing approximately 1.39% over this period. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex opened flat but rallied to close 0.32% higher at 83,580.40, just 3.09% shy of its 52-week high of 86,159.02. Mega-cap stocks led the gains, while the Sensex remains below its 50-day moving average, though the 50DMA itself is positioned above the 200DMA, indicating a mixed but cautiously optimistic market environment.
Long-Term Performance and Relative Comparison
TTK Healthcare’s one-year performance has been notably weaker than the benchmark indices. The stock has delivered a negative return of -27.16% over the past year, while the Sensex has gained 7.07% in the same period. This underperformance extends beyond the last year, with the stock lagging the BSE500 index across three years, one year, and three months, highlighting persistent challenges in generating shareholder value.
The 52-week high for TTK Healthcare was Rs.1,402, indicating a substantial decline of approximately 32.4% from that peak to the current low. This gap underscores the stock’s struggle to regain investor confidence amid evolving market conditions.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Financial Metrics and Growth Trends
TTK Healthcare’s long-term growth has been modest. Over the last five years, net sales have increased at an annualised rate of 6.99%, while operating profit has grown at 15.42% annually. These figures suggest moderate expansion but fall short of robust growth expectations for a company of its size and sector.
In the half-year ended December 2025, the company reported its lowest cash and cash equivalents at Rs.600.89 crores, indicating a tighter liquidity position compared to previous periods. Additionally, the debtors turnover ratio stood at 7.40 times, also the lowest in recent history, reflecting slower collection cycles or increased receivables.
Non-operating income accounted for a significant 80.43% of the quarterly profit before tax, signalling that a large portion of earnings is derived from sources outside the core business operations. This reliance on non-operating income may raise questions about the sustainability of profit levels.
Shareholding and Market Perception
Despite TTK Healthcare’s sizeable market presence, domestic mutual funds hold a minimal stake of just 0.01%. Given that mutual funds typically conduct thorough research and maintain significant positions in fundamentally strong companies, this limited exposure could indicate a cautious stance towards the stock’s current valuation or business prospects.
Valuation and Profitability Indicators
The company maintains a low average debt-to-equity ratio of zero, reflecting a conservative capital structure with minimal leverage. Return on equity (ROE) stands at 6.5%, which, while positive, is modest relative to industry standards.
TTK Healthcare’s price-to-book value ratio is 1.2, suggesting the stock trades at a slight premium compared to its book value. However, this premium is higher than the average historical valuations of its peers, indicating that the market may be pricing in expectations not fully supported by recent performance.
Over the past year, profits have increased by 2.4%, a marginal improvement that contrasts with the stock’s negative return of -27.16%. The company’s price/earnings to growth (PEG) ratio is 8.2, a figure that points to a stretched valuation relative to earnings growth, which may contribute to the subdued market sentiment.
Is TTK Healthcare Ltd. your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Mojo Score and Analyst Ratings
TTK Healthcare currently holds a Mojo Score of 37.0, placing it in the 'Sell' category. This represents a downgrade from its previous 'Hold' rating as of 21 Jul 2025. The market capitalisation grade is rated at 3, reflecting its mid-tier size within the diversified sector.
The downgrade reflects concerns over the company’s growth trajectory, valuation metrics, and recent financial performance, which have collectively influenced the stock’s downward movement to its current 52-week low.
Summary of Key Concerns
In summary, TTK Healthcare’s stock decline to Rs.947.65 is underpinned by a combination of factors including subdued sales growth, limited profit expansion, a high proportion of non-operating income contributing to profits, and a valuation premium that appears inconsistent with recent earnings trends. The minimal stake held by domestic mutual funds further highlights a cautious market stance.
While the broader market has shown resilience, led by mega-cap stocks and a rising Sensex, TTK Healthcare’s share price continues to reflect the challenges it faces within its diversified sector.
Unlock special upgrade rates for a limited period. Start Saving Now →
